Rescue of a biologically active Epstein-Barr virus from nonproducer cells.
We recently established an epithelial/hybrid cell line, A2L/AH, by fusion of 8-azaguanine-resistant epithelial cells, Ad-AH, with a nonproducer lymphoblastoid cell line, A2L, using lymphocytes derived from the human nasopharynx transformed with the B95-8 strain of Epstein-Barr virus. The treatment of the parental A2L lymphoid cells with iododeoxyuridine led to the expression of Epstein-Barr virus early antigen, but neither virus capsid antigen or induction of Epstein-Barr virus DNA synthesis was observed. However, the treatment of the A2L/AH hybrid cells with iododeoxyuridine led to early antigen, virus capsid antigen and virus DNA synthesis, and the formation of virus particles. The virus rescued from the A2L/AH hybrid cells transforms human cord blood lymphocytes but is not able to induce early antigen in superinfected Raji cells.
D000956:Antigens, Viral / Q000032:analysis; D036022:Capsid Proteins; D002460:Cell Line; D002472:Cell Transformation, Viral; D004279:DNA, Viral / Q000032:analysis; D005814:Genes, Viral; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000502:physiology*; D006801:Humans; D006822:Hybrid Cells; D008214:Lymphocytes / Q000382:microbiology*; D009305:Nasopharynx / Q000382:microbiology; D014779:Virus Replication
D000956:Antigens, Viral; D036022:Capsid Proteins; D004279:DNA, Viral; C041788:Epstein-Barr viral capsid antigen; C033305:Epstein-Barr virus early antigen